Skip to main content
SpringerLink
Log in

Caveolin-1 in Brain Tumors

  • Chapter
  • First Online:
Caveolins in Cancer Pathogenesis, Prevention and Therapy

Part of the book series: Current Cancer Research ((CUCR))

  • 358 Accesses

Abstract

Increasing evidences in the last years suggested a possible involvement of caveolin-1 (cav-1) in the biology of brain tumors. In vitro studies on glioma cell lines as well as immuno-phenotyping of primary human gliomas reported that cav-1 expression in brain tumors varies according to the histotype and grade, and could bear prognostic significance in specific tumor subsets. In addition, due to the described irradiation-dependent modulation of cav-1 expression in glioma cells and the presence of data highlighting heterogeneous trafficking dynamics involving the EGFR-cav-1 coupling in solid tumors, it can be envisaged that cav-1 could soon be taken into account in the perspective of novel therapeutic approaches for malignant brain tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Liu P, Rudick M, Anderson RG (2002) Multiple functions of caveolin-1. J Biol Chem 277:41295–41298

    Article  PubMed  CAS  Google Scholar 

  2. Shaul PW, Anderson RG (1998) Role of plasmalemmal caveolae in signal transduction. Am J Physiol 275:L843–L851

    PubMed  CAS  Google Scholar 

  3. Burgermeister E, Liscovitch M, Rocken C et al (2008) Caveats of caveolin-1 in cancer progression. Cancer Lett 268:187–201

    Article  PubMed  CAS  Google Scholar 

  4. Goetz JG, Lajoie P, Wiseman SM et al (2008) Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev 27:715–735

    Article  PubMed  CAS  Google Scholar 

  5. Lisanti MP, Scherer PE, Tang Z et al (1994) Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis. Trends Cell Biol 4:231–235

    Article  PubMed  CAS  Google Scholar 

  6. Ando T, Ishiguro H, Kimura M et al (2007) The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncol Rep 18:601–609

    PubMed  CAS  Google Scholar 

  7. Bender FC, Reymond MA, Bron C et al (2000) Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 60:5870–5878

    PubMed  CAS  Google Scholar 

  8. Campbell L, Gumbleton M, Griffiths DF (2003) Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer 89:1909–1913

    Article  PubMed  CAS  Google Scholar 

  9. Karam JA, Lotan Y, Roehrborn CG et al (2007) Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 67:614–622

    Article  PubMed  Google Scholar 

  10. Lee SW, Reimer CL, Oh P et al (1998) Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16:1391–1397

    Article  PubMed  CAS  Google Scholar 

  11. Phuoc NB, Ehara H, Gotoh T et al (2007) Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma. Urology 69:843–848

    Article  PubMed  Google Scholar 

  12. Wiechen K, Diatchenko L, Agoulnik A et al (2001) Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 159:1635–1643

    Article  PubMed  CAS  Google Scholar 

  13. Wiechen K, Sers C, Agoulnik A et al (2001) Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol 158:833–839

    Article  PubMed  CAS  Google Scholar 

  14. Witkiewicz AK, Casimiro MC, Dasgupta A et al (2009) Towards a new “stromal-based” classification system for human breast cancer prognosis and therapy. Cell Cycle 8:1654–1658

    Article  PubMed  CAS  Google Scholar 

  15. Witkiewicz AK, Dasgupta A, Sotgia F et al (2009) An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 174:2023–2034

    Article  PubMed  CAS  Google Scholar 

  16. Cameron PL, Ruffin JW, Bollag R et al (1997) Identification of caveolin and caveolin-related proteins in the brain. J Neurosci 17:9520–9535

    PubMed  CAS  Google Scholar 

  17. Ikezu T, Ueda H, Trapp BD et al (1998) Affinity-purification and characterization of caveolins from the brain: differential expression of caveolin-1, -2, and -3 in brain endothelial and astroglial cell types. Brain Res 804:177–192

    Article  PubMed  CAS  Google Scholar 

  18. Megias L, Guerri C, Fornas E et al (2000) Endocytosis and transcytosis in growing astrocytes in primary culture. Possible implications in neural development. Int J Dev Biol 44:209–221

    PubMed  CAS  Google Scholar 

  19. Virgintino D, Robertson D, Errede M et al (2002) Expression of caveolin-1 in human brain microvessels. Neuroscience 115:145–152

    Article  PubMed  CAS  Google Scholar 

  20. Bagnoli M, Tomassetti A, Figini M et al (2000) Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. Oncogene 19:4754–4763

    Article  PubMed  CAS  Google Scholar 

  21. Koleske AJ, Baltimore D, Lisanti MP (1995) Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 92:1381–1385

    Article  PubMed  CAS  Google Scholar 

  22. Racine C, Belanger M, Hirabayashi H et al (1999) Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem Biophys Res Commun 255:580–586

    Article  PubMed  CAS  Google Scholar 

  23. Suzuki T, Suzuki Y, Hanada K et al (1998) Reduction of caveolin-1 expression in tumorigenic human cell hybrids. J Biochem 124:383–388

    PubMed  CAS  Google Scholar 

  24. Engelman JA, Zhang XL, Lisanti MP (1998) Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 436:403–410

    Article  PubMed  CAS  Google Scholar 

  25. Fra AM, Mastroianni N, Mancini M et al (1999) Human caveolin-1 and caveolin-2 are closely linked genes colocalized with WI-5336 in a region of 7q31 frequently deleted in tumors. Genomics 56:355–356

    Article  PubMed  CAS  Google Scholar 

  26. Hurlstone AF, Reid G, Reeves JR et al (1999) Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene 18:1881–1890

    Article  PubMed  CAS  Google Scholar 

  27. Lin JC, Scherer SW, Tougas L et al (1996) Detailed deletion mapping with a refined physical map of 7q31 localizes a putative tumor suppressor gene for breast cancer in the region of MET. Oncogene 13:2001–2008

    PubMed  CAS  Google Scholar 

  28. Silva WI, Maldonado HM, Lisanti MP et al (1999) Identification of caveolae and caveolin in C6 glioma cells. Int J Dev Neurosci 17:705–714

    Article  PubMed  CAS  Google Scholar 

  29. Silva WI, Maldonado HM, Velazquez G et al (2005) Caveolin isoform expression during differentiation of C6 glioma cells. Int J Dev Neurosci 23:599–612

    Article  PubMed  CAS  Google Scholar 

  30. Cameron PL, Liu C, Smart DK et al (2002) Caveolin-1 expression is maintained in rat and human astroglioma cell lines. Glia 37:275–290

    Article  PubMed  Google Scholar 

  31. Hayashi K, Matsuda S, Machida K et al (2001) Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 61:2361–2364

    PubMed  CAS  Google Scholar 

  32. Bonuccelli G, Casimiro MC, Sotgia F et al (2009) Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature. Am J Pathol 174:1650–1662

    Article  PubMed  CAS  Google Scholar 

  33. Lee H, Park DS, Razani B et al (2002) Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 161:357–369

    Google Scholar 

  34. Mercier I, Bryant KG, Sotgia F et al (2009) Using Caveolin-1 epithelial immunostaining patterns to stratify human breast cancer patients and predict the Caveolin-1 (P132L) mutation. Cell Cycle 8:1396–1401

    Article  PubMed  CAS  Google Scholar 

  35. Forget MA, Desrosiers RR, Del M et al (2002) The expression of rho proteins decreases with human brain tumor progression: potential tumor markers. Clin Exp Metastasis 19:9–15

    Article  PubMed  CAS  Google Scholar 

  36. Abulrob A, Giuseppin S, Andrade MF et al (2004) Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene 23:6967–6979

    Article  PubMed  CAS  Google Scholar 

  37. Cassoni P, Senetta R, Castellano I et al (2007) Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas. Am J Surg Pathol 31:760–769

    Article  PubMed  Google Scholar 

  38. Barresi V, Buttarelli FR, Vitarelli EE et al (2009) Caveolin-1 expression in diffuse gliomas: correlation with the proliferation index, epidermal growth factor receptor, p53, and 1p/19q status. Hum Pathol 40:1738–1746

    Article  PubMed  CAS  Google Scholar 

  39. Ichimura K, Ohgaki H, Kleihues P et al (2004) Molecular pathogenesis of astrocytic tumours. J Neurooncol 70:137–160

    Article  PubMed  Google Scholar 

  40. Misra A, Pellarin M, Nigro J et al (2005) Array comparative genomic hybridization identifies genetic subgroups in grade 4 human astrocytoma. Clin Cancer Res 11:2907–2918

    Article  PubMed  CAS  Google Scholar 

  41. Wiltshire RN, Herndon JE 2nd, Lloyd A et al (2004) Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. J Mol Diagn 6:166–179

    Article  PubMed  CAS  Google Scholar 

  42. Nigro JM, Misra A, Zhang L et al (2005) Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 65:1678–1686

    Article  PubMed  CAS  Google Scholar 

  43. Phillips HS, Kharbanda S, Chen R et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173

    Article  PubMed  CAS  Google Scholar 

  44. Godard S, Getz G, Delorenzi M et al (2003) Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 63:6613–6625

    PubMed  CAS  Google Scholar 

  45. Sallinen SL, Sallinen PK, Haapasalo HK et al (2000) Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60:6617–6622

    PubMed  CAS  Google Scholar 

  46. Martin S, Cosset EC, Terrand J et al (2009) Caveolin-1 regulates glioblastoma aggressiveness through the control of alpha(5)beta(1) integrin expression and modulates glioblastoma responsiveness to SJ749, an alpha(5)beta(1) integrin antagonist. Biochim Biophys Acta 1793:354–367

    Article  PubMed  CAS  Google Scholar 

  47. Senetta R, Trevisan E, Ruda R et al (2009) Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas. J Neuropathol Exp Neurol 68:425–431

    Article  PubMed  CAS  Google Scholar 

  48. Iwamoto FM, Nicolardi L, Demopoulos A et al (2008) Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol 88:293–298

    Article  PubMed  Google Scholar 

  49. Kujas M, Lejeune J, Benouaich-Amiel A et al (2005) Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol 58:322–326

    Article  PubMed  CAS  Google Scholar 

  50. Mariani L, Deiana G, Vassella E et al (2006) Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J Clin Oncol 24:4758–4763

    Article  PubMed  CAS  Google Scholar 

  51. Weller M, Berger H, Hartmann C et al (2007) Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13:6933–6937

    Article  PubMed  CAS  Google Scholar 

  52. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714

    Article  PubMed  CAS  Google Scholar 

  53. van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722

    Article  PubMed  Google Scholar 

  54. Kouwenhoven MC, Kros JM, French PJ et al (2006) 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 42:2499–2503

    Article  PubMed  CAS  Google Scholar 

  55. Jodoin J, Demeule M, Fenart L et al (2003) P-glycoprotein in blood-brain barrier endothelial cells: interaction and oligomerization with caveolins. J Neurochem 87:1010–1023

    Article  PubMed  CAS  Google Scholar 

  56. Song L, Ge S, Pachter JS (2007) Caveolin-1 regulates expression of junction-associated proteins in brain microvascular endothelial cells. Blood 109:1515–1523

    Article  PubMed  CAS  Google Scholar 

  57. Regina A, Jodoin J, Khoueir P et al (2004) Down-regulation of caveolin-1 in glioma vasculature: modulation by radiotherapy. J Neurosci Res 75:291–299

    Article  PubMed  CAS  Google Scholar 

  58. Engelman JA, Wykoff CC, Yasuhara S et al (1997) Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 272:16374–16381

    Article  PubMed  CAS  Google Scholar 

  59. Galbiati F, Volonte D, Engelman JA et al (1998) Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 17:6633–6648

    Article  PubMed  CAS  Google Scholar 

  60. Brown G, Rixon HW, Sugrue RJ (2002) Respiratory syncytial virus assembly occurs in GM1-rich regions of the host-cell membrane and alters the cellular distribution of tyrosine phosphorylated caveolin-1. J Gen Virol 83:1841–1850

    PubMed  CAS  Google Scholar 

  61. Williams TM, Lisanti MP (2005) Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol 288:C494–C506

    Article  CAS  Google Scholar 

  62. Hurtt MR, Moossy J, Donovan-Peluso M et al (1992) Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 51:84–90

    Article  PubMed  CAS  Google Scholar 

  63. Lo HW, Cao X, Zhu H et al (2008) Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 14:6042–6054

    Article  PubMed  CAS  Google Scholar 

  64. Schlegel J, Merdes A, Stumm G et al (1994) Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 56:72–77

    Article  PubMed  CAS  Google Scholar 

  65. Schlegel J, Stumm G, Brandle K et al (1994) Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J Neurooncol 22:201–207

    Article  PubMed  CAS  Google Scholar 

  66. Mendrzyk F, Korshunov A, Benner A et al (2006) Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 12:2070–2079

    Article  PubMed  CAS  Google Scholar 

  67. Khan EM, Heidinger JM, Levy M et al (2006) Epidermal growth factor receptor exposed to oxidative stress undergoes Src- and caveolin-1-dependent perinuclear trafficking. J Biol Chem 281:14486–14493

    Article  PubMed  CAS  Google Scholar 

  68. Senetta R, Miracco C, Lanzafame S et al (2011) Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavourable outcomes. Neuro Oncol 13:176–183

    Article  PubMed  CAS  Google Scholar 

  69. Huang F, Reeves K, Han X et al (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67:2226–2238

    Article  PubMed  CAS  Google Scholar 

  70. Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513–609

    Article  PubMed  CAS  Google Scholar 

  71. Dittmann K, Mayer C, Kehlbach R et al (2008) Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer 7:69

    Article  PubMed  Google Scholar 

  72. Wang J, Wakeman TP, Lathia JD et al (2010) Notch promotes radioresistance of glioma stem cells. Stem cells 28:17-28

    Google Scholar 

  73. Golding SE, Morgan RN, Adams BR et al (2009) Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther 8:730–738

    Article  PubMed  CAS  Google Scholar 

  74. Mukherjee B, McEllin B, Camacho CV et al (2009) EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 69:4252–4259

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences and Human Oncology, University of Turin, Turin, Italy

    Rebecca Senetta & Paola Cassoni

Authors
  1. Rebecca Senetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paola Cassoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paola Cassoni .

Editor information

Editors and Affiliations

  1. Kimmel Cancer Center, Thomas Jefferson University, S. 10th Street 233, Philadelphia, 19107, Pennsylvania, USA

    Isabelle Mercier

  2. Bluemle Bldg, Rm 939, Department of Stem Cell Biology and Rege, Thomas Jefferson University, S. 10th Street 233, Philadelphia, 19107, Pennsylvania, USA

    Jean-François Jasmin

  3. Kimmel Cancer Center, Thomas Jefferson University, S. 10th Street 233, Philadelphia, 19107, Pennsylvania, USA

    Michael P. Lisanti

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Senetta, R., Cassoni, P. (2012). Caveolin-1 in Brain Tumors. In: Mercier, I., Jasmin, JF., Lisanti, M. (eds) Caveolins in Cancer Pathogenesis, Prevention and Therapy. Current Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1001-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-1001-0_4

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-1000-3

  • Online ISBN: 978-1-4614-1001-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation